Hosted on MSN1mon
Roche's Susvimo gets FDA approval for diabetic macular edema
Roche's (OTCQX:RHHBY) Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with ...
pharmaphorum1d
FDA clears Roche's Susvimo implant for eye disease wet AMD
Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.
pharmaphorum1mon
FDA expands label for Roche's eye disease implant Susvimo
The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema (DME), a leading cause of vision loss and blindness.
MarketWatch1mon
Roche: FDA Approves Susvimo for Treatment of Diabetic Macular Edema
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
UBS lifts Roche stock rating to Buy, raises target to CHF338
In other recent news, Genentech, a part of Roche Group, announced the FDA's approval of Susvimo for the treatment of diabetic macular edema (DME). The approval follows positive results from the ...